Stephen Friend, Nov 10, 2011. Berlin9, Washington, DC

1. gd oi Nw nn o e ae w

2. Reality: Overlapping Pathways

3. The value of appropriate representations/ maps

6. WHY
NOT
USE
“DATA
INTENSIVE”
SCIENCE
TO
BUILD
BETTER
DISEASE
MAPS?

7. what will it take to understand disease?
DNA
RNA
PROTEIN
(dark
maHer)
MOVING
BEYOND
ALTERED
COMPONENT
LISTS

8. 2002 Can one build a “causal” model?

9. (Eric Schadt)

11. We still consider much clinical research as if we we
hunter gathers! not sharing
- .

12. Clinical/genomic data
are accessible but minimally usable
Little incentive to annotate and curate
data for other scientists to use

13. Mathematical
models of disease
are not built to be
reproduced or
versioned by others

14. Assumption that genetic alterations
in human conditions should be owned

15. Lack of standard forms for future rights and consentss

16. sharing as an adoption of common standards..
Clinical Genomics Privacy IP

17. Publication Bias- Where can we find the (negative) clinical data?

18. Sage Mission
Sage Bionetworks is a non-profit organization with a vision to
create a commons where integrative bionetworks are evolved by
contributor scientists with a shared vision to accelerate the
elimination of human disease
Building Disease Maps Data Repository
Commons Pilots Discovery Platform
Sagebase.org

19. Sage Bionetworks Collaborators
 Pharma Partners
 Merck, Pfizer, Takeda, Astra Zeneca,
Amgen, Johnson &Johnson
 Foundations
 Kauffman CHDI, Gates Foundation
 Government
 NIH, LSDF
 Academic
 Levy (Framingham)
 Rosengren (Lund)
 Krauss (CHORI)
 Federation
 Ideker, Califarno, Butte, Schadt 19

21. sage bionetworks synapse project
Watch What I Do, Not What I Say Reduce, Reuse, Recycle
My Other Computer is Amazon
Most of the People You Need to Work with
Don’t Work with You

22. M e
ogn g ow gd oi Nn
oi g e e own wg
i A
M
S
FOR
MAP
i
ow
PLAT
ow i nn i o g
EW N
RULES GOVERN

23. CTCAP
Clinical Trial Comparator Arm Partnership “CTCAP”
Strategic Opportunities For Regulatory Science
Leadership and Action
FDA
September 27, 2011

24. Shared clinical/genomic data sharing and analysis will
maximize clinical impact and enable discovery
• Graphic
of
curated
to
qced
to
models

25. Arch2POCM
Restructuring
the
PrecompePPve
Space
for
Drug
Discovery
How
to
potenPally
De-­‐Risk
High-­‐Risk
TherapeuPc
Areas

27. The
FederaPon

29. sage federation:
model of biological age
Faster Aging
U M i l r i nnowS
Slower Aging
e
Clinical Association
- Gender
- BMI
g
- Disease
Age Differential Genotype Association
Gene Pathway Expression
i
i owoe
o e U i nS
B

30. Sage
Congress
Project
April
20
2012
RA
Parkinson’s
Asthma
(Responders
CompePPons)

31. Actionable Cancer Network Models
And Open Medical Information Systems